Skip to main content
Top

Cancer Immunology, Immunotherapy

Issue 1/1998

Content (7 Articles)

ORIGINAL ARTICLE

Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells

Kun Li, Medi Adibzadeh, Thomas Halder, Hubert Kalbacher, Susanne Heinzel, Claudia Müller, Jesper Zeuthen, Graham Pawelec

ORIGINAL ARTICLE

Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01

Helma M. Prinssen, Carla F. M. Molthoff, René H. M. Verheijen, Tim J. Broadhead, Peter Kenemans, Jan C. Roos, Quentin Davies, Arjan C. van Hof, Malcolm Frier, Wim den Hollander, Abraham J. Wilhelm, Terry S. Baker, Mark Sopwith, E. Malcolm Symonds, Alan C. Perkins

ORIGINAL ARTICLE

Effect of interleukin-8 on production of tumor-associated substances and autocrine growth of human liver and pancreatic cancer cells

Megumi Miyamoto, Yukihiro Shimizu, Kazuhiko Okada, Yoshiro Kashii, Kiyohiro Higuchi, Akiharu Watanabe

ORIGINAL ARTICLE

Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma

Nitya G. Chakraborty, Jonathan R. Sporn, Anne F. Tortora, Scott H. Kurtzman, Harold Yamase, M. T. Ergin, Bijay Mukherji

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine